Stock analysis, AI verdict, fundamentals & technical signals
Rating: BUY
Price: $159.89 Analyst target: $331.22 Upside: 107.15%
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
See the full interactive analysis & chart →Informational only — not investment advice.